

1 **Type of Issue** Initial Public Offer

2 **Issue Size (Rs. Mn)** 18,417.59*

*Source: Prospectus

3 **Grade of issue along with name of the rating agency**

Name NA

Grade NA

4 **Subscription Level (Number of times)** 70.85

Source: Basis of allotment

5 **QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges**

Particulars	%
(i) On Allotment *	3.56%
(ii) at the end of the Quarter immediately after the listing of the issue (June 30, 2024)*	3.79%
(iii) at the end of 1st FY (March 31, 2025)	4.96%
(iv) at the end of 2nd FY (March 31, 2026)	18.43%
(v) at the end of 3rd FY (March 31, 2027)**	N.A.

~~Shareholding pattern disclosed to Stock~~

~~Exchanges~~

** QIB Holding not disclosed as reporting for relevant period has not been completed.

6 **Financials of the issuer**

(Rs. Million)

Parameters	1st FY (March 31, 2025)	2nd FY (March 31, 2026)	3rd FY (March 31, 2027) *
Income from operations	28,393	35,105	Not Available
Net Profit for the period	4,067	4,011	Not Available
Paid-up equity share capital	479	481	Not Available
Reserves excluding revaluation reserves	25,677	30,906	Not Available

* Financials not available as reporting for the relevant years has not been completed.

7 Trading Status

The equity shares of the Company are listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")
The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Active
(ii) at the end of 2nd FY (March 31, 2026) *	Active
(iii) at the end of 3rd FY (March 31, 2027) *	Not Available

** Trading status not disclosed as the relevant fiscal years have not been completed.*

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025) *	-	-
(ii) at the end of 2nd FY (March 31, 2026) *	Dr. Georgia Nikolakopoulou Papathomas	Appointed
	Neeraj Bharadwaj	Resignation
	Neeraj Bharadwaj	Appointed
	Jill Mary De Simone	Appointed
(iii) at the end of 3rd FY (March 31, 2027) *	Not Available	Not Available

** Changes in Directors of Issuer not updated as the relevant financial years have not been completed*

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	(i) Repayment/prepayment of indebtedness of one of our Material Subsidiaries, ILSL Holdings, Inc.(INR 3,913.35 mn) (ii) Funding the capital expenditure requirements of our Company and one of our Material Subsidiaries, Indegene, Inc. (INR 1,029.16 mn) (ii) General corporate purposes (INR 2,301.20* mn)
(ii) Actual utilization	(i) Repayment/prepayment of indebtedness of one of our Material Subsidiaries, ILSL Holdings, Inc.(INR 395.00 Cr)# (ii) Funding the capital expenditure requirements of our Company and one of our Material Subsidiaries, Indegene, Inc. (INR 64.49 Cr) (ii) Technology, Cybersecurity and Cloud infrastructure related cost (INR 34.99 Cr)* (ii) General corporate purposes (INR 230.12 Cr)
<i>#The company has repaid loan of USD 47.20 mn outstanding in the books of ILSL Holdings Inc. (material subsidiary), in line with Object 1. The actual payment in USD remained the same but in INR terms, it was Rs. 395.00 crore, higher by Rs. 3.67 crore (from the amount mentioned in the RHP) due to the foreign exchange rate difference between the date considered in RHP and actual payment date.</i>	
<i>*The company has passed Special Resolution dated August 12, 2025, for approval of variation in utilization of Initial Public</i>	
(iii) Reasons for deviation, if any	NA
<i>Last Updated on 31/5/2026</i>	

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not available*
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not available*
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not available*

**Will be updated once monitoring report is uploaded on the Stock Exchanges website*

12 Pricing Data

Designated Stock Exchange	NSE
Issue Price (Rs.)	452.00
Listing Date	13-May-24

Price parameters	At close of listing day- 13-May-24	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2025)		
				Closing price	High	Low
Market Price	570.90	561.75	573.40	578.50	736.30	470.10
Nifty 50 Index	22,104.50	23,264.85	24,367.50	23,519.35	26,277.35	21,281.45

Sectoral Index Not comparable to any of the available sectoral indices

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2026)*			As at the end of the 3rd FY after the listing of the issue (31st March, 2027)*		
	Closing price	High	Low	Closing price	High	Low
Market Price	434.60	632.90	414.00	Not available*	Not available*	Not available*
Nifty 50 Index	22,331.40	26,373.20	21,743.70	Not available*	Not available*	Not available*

Sectoral Index Not comparable to any of the available sectoral indices

* The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio		As disclosed in offer document, at the end of FY 2023	At the end of 1st FY (March 31, 2025)	At the end of 1st FY (March 31, 2026)***	At the end of 1st FY (March 31, 2027)***
EPS (Basic)	Company*	12.03	4.91	16.72	Not Available
	Peer Group & Industry Avg**	No peer group	No peer group	No peer group	No peer group
P/E	Company [#]	37.57	117.82	25.99	Not Available
	Peer Group & Industry Avg**	No peer group	No peer group	No peer group	No peer group

RONW	Company*	25.02%	15.55%	12.78%	Not Available
	Peer Group & Industry Avg**	No peer group	No peer group	No peer group	No peer group
NAV per share	Company*	48.1	108.98	130.51	Not Available
	Peer Group & Industry Avg**	No peer group	No peer group	No peer group	No peer group

Notes

*Data / Calculations for the Fiscal Ended / as at March 31, 2023

**There are no listed companies in India and globally that engage in a business that is similar to that of our Company. Accordingly, we have not provided an industry comparison in relation to our Company

*** The pricing data is not disclosed as the

#P/E Ratio of the Company has been computed based on the Offer Price (Cap) divided by the basic EPS.

14 Any other material information

Particulars	Date
Listing of Equity Shares	13-May-24
CliniOps Announces Strategic Partnership with Indegene to Accelerate Clinical Trials	9-Jan-25
Deloitte Haskins and Sells were appointed as the Auditors	30-Jan-25
Re-appointment of Dr. Georgia Nikolakopoulou Papathomas as an Independent Woman Director for a	27-May-25
Record Date for the purpose of final dividend for the year ended 31 March 2025	27-May-25
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CA Dawn Investments	5-Jun-25
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd	5-Jun-25
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG	5-Jun-25
Shareholders approval for Approval of Variation in Utilization of Initial Public Offering (“IPO”) Proceeds	13-Aug-25
Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Neeraj Bharadwaj as Non-Executive Independent Director	19-Dec-25
The Board also approved allotment under ESOP Plan 2020 and RSU Plan 2020 of 149635 Shares.	19-Dec-25
Indegene’s subsidiaries (Indegene Inc. and Trilogy Writing & Consulting GmbH) signed an SPA to acquire 100% of Trilogy Writing & Consulting Inc. On completion, the target will shift from being a subsidiary of Trilogy GmbH to a wholly owned subsidiary of Indegene Inc.	31-Dec-25

the Nomination and Remuneration Committee on, i.e., December 31, 2025, has approved grants under the RSU 2020 Plan of 508368 Options.	31-Dec-25
Indegene's step-down subsidiaries, Indegene Aptilon Services Inc. and Trilogy Writing & Consulting Inc., merged on Jan 1, 2026, to form Indegene Healthcare Canada Inc.	1-Jan-26
Nomination and Remuneration Committee has approved the appointment of Ms. Jill Mary De Simone as Additional Director (Non-Executive Independent Director), subject to the approval of shareholders	22-Jan-26
Allotment of 13332 securities pursuant to ESOP/ESPS	29-Jan-26
The Board approved allotment of shares under ESOP 2020 and RSU 2020 plans, both with and without bonus elements of 327880 Shares.	20-Feb-26
Indegene Healthcare UK Ltd. signed an SPA on March 1, 2026 to acquire 100% stakes in two UK entities; both will cease existing parent subsidiaries and become wholly owned subsidiaries of Indegene Healthcare UK Ltd.	1-Mar-26
The Board approved allotment of shares under the RSU 2020 plan, both with and without bonus elements of 93390 Shares.	18-Mar-26
Recommended a final dividend of Rs. 2.25/- per equity share of Rs. 2/- each	29-Apr-26
Allotment of 52951 securities pursuant to ESOP/ESPS	29-Apr-26
An income tax demand notice u/s 156 of the Income Tax Act, 1961 from the Income Tax Department for the Assessment Year 2023-24 (corresponding to the Financial Year 2022-23) with an income tax demand of INR 43,68,84,410 (including interest).	5-May-26
<i>Note: For further updates and information, please refer Stock Exchange websites</i>	